

SEQUENCE LISTING

<110> AplaGen GmbH

<120> Isosteric Transformation

<130> 050633wo Me/FM

<140> PCT/EP2005/051256

<141> 2005-03-17

<150> EP 04006354.7

<151> 2004-03-17

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic
peptide

<400> 1

Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His Leu Leu Leu Asp Leu
1 5 10 15

Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr
20 25

<210> 2

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic
peptide

<400> 2

Tyr Asn Asn Ile Gly Asn Leu Ile Met Gln Leu Asp Leu Leu Leu His
1 5 10 15

Glu Leu Gln Leu Gln Thr Lys Lys Thr Ser
20 25

<210> 3

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic peptide

<400> 3

Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln
1 5 10 15

<210> 4

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic peptide

<400> 4

Gln Gly Lys Cys Val Trp Thr Leu Gly Gly Phe His Cys Ser Tyr Thr
1 5 10 15

<210> 5

<211> 15

<212> PRT

<213> Artificial Sequence

<220> amino acid

<221> MUTAGEN

<222> 9

<223> 5-aminovaleric acid

<223> Description of Artificial Sequence:synthetic peptide

<400> 5

Gln Gly Lys Cys Val Trp Thr Leu Xaa Phe His Cys Ser Tyr Thr
1 5 10